Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Sirolimus for Refractory Oral cGVHD
NCT02123966Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in chronic graft-versus-host disease (cGVHD), sponsored by Dana-Farber Cancer Institute. Started Jul 2014; status: terminated.
02
Drugs
sirolimus
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02123966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02123966.